🔓 Unlock the full profile of Thorsten Graef (Artiva Biotherapeutics), including verified contact details, financial insights, and professional associations.
See Thorsten Graef Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: tho*****@art******.com
Mobile: 71539*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Thorsten Graef is the founder of AVAIL Clinical Consulting, Inc, which was established in May 2025.
- Before founding AVAIL, Thorsten served as Chief Medical Officer at Artiva Biotherapeutics from June 2022 to April 2025, contributing significantly to the company's strategic direction and clinical operations.
- Prior to Artiva, Thorsten held the position of Chief Medical Officer at Acepodia from May 2021 to April 2022, overseeing clinical development initiatives.
- Thorsten's experience includes a role as Vice President of Oncology Early Development at AbbVie from March 2019 to April 2021, where valuable insights were gained in oncology drug development.
- At Pharmacyclics, an AbbVie Company, Thorsten was the Head of Development from December 2014 to February 2019, leading efforts to advance innovative therapies.
- From 2012 to October 2014, Thorsten served as Vice President of Clinical Research at Pharmacyclics, focusing on clinical study design and execution.
- Earlier in the career, Thorsten was a Medical Director at Merck Sharp & Dohme from May 2009 to October 2012, where significant contributions were made to clinical research.
- Thorsten began his career as a Staff Physician at the University of Düsseldorf from January 2002 to January 2006, laying a strong foundation in clinical practice.
- Artiva Biotherapeutics, founded in 2019, operates as a publicly traded company under the symbol ARTV on NASDAQ and has experienced substantial growth.
- The company has demonstrated a remarkable 46.3% growth rate in headcount over 24 months, reflecting its expanding influence in the biotechnology sector.